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A c c e p t e d M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 A c c e p t e d M a n u s c r i p t This technology offers a potential solution to current obstacles in regenerative medicine, disease modelling and whole organ tissue engineering. Tissue engineers seek to solve this problem by engineering liver 'organoids'; laboratory created organs which can function as a liver in vivo [4] [5] [6] [7] . The 3D environment exerts extensive influence on the behaviour and function of hepatocytes 6, 8 . With this in mind, tissue engineers employ scaffold manufacturing technologies to create structures which encompass key characteristics of the native 3D ECM [9] [10] [11] [12] [13] [14] . Several different methods of creating a scaffold are in use, and they can be made from a myriad of substances; both natural and synthetic 15 , and enhanced with bio-decoration methods 8 . There has been particular focus on decellularization, which provides an ECM bioscaffold with the 3D site-specific vasculature required for hepatocyte function upon their repopulation of the organ 16 . Decellularized organs have been repopulated with hepatocytes and endothelial cells which subsequently survive and exhibit some level of function, clearly demonstrating the importance of the ECM in supporting hepatocyte survival and phenotype [17] [18] [19] [20] [21] . However, decellularization requires a human or animal source of whole, undamaged organs and while research is showing great promise, the field is fragmented and to date no scaffold has been created which allows hepatocytes to function as well as in vivo 22, 23 .
Synthetic biology and genetic engineering are vital tools for tissue engineers and have been used to alter gene expression, enhance intracellular imaging and study fundamental processes in hepatocytes [24] [25] [26] . Recently, synthetic biology tools have been successfully employed to direct both stem cell lineage and fate in 3D constructs 27, 28 , in the manipulation of biofilms for cell culture 29 and in the production of therapeutic proteins in in vivo systems 30, 31 Page 4 of 26 AUTHOR SUBMITTED MANUSCRIPT -BPEX-100928. R2   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t demonstrating the ability of synthetic biology techniques to manipulate 3D environments and thus their potential benefit to the field of tissue engineering. Groundbreaking CRISPR [32] [33] [34] and minicircle vector [35] [36] [37] 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t
With the potential of synthetic biology for manipulation of protein production in mind, we set out to address this problem; developing a novel bio-active hybrid scaffold which possesses the potential for customizatioon of the ECM microenvironment. To date, no bioengineers have combined the promising fields of scaffold manufacture, decellularized tissue and synthetic biology. Here we report the first use of a sacrificial, transfected cell line to bio-functionalise an electrospun polymer scaffold for liver tissue engineering. We have successfully decellularized the bio-functionalised scaffold, and validated the platform using cells representative of the liver, HepG2s.
Materials and Methods

Electrospinning
A 10% wt/vol solution of poly-L-lactic acid (Goodman) and hexafluoroisopropanol (Manchester Organics) was dissolved overnight at room temperature with agitation. Solutions were placed into a 10ml syringe and pumped using syringe pump EP-H11 (Harvard Apparatus) into the EC-DIG electrospinning system (IME technologies) via a 27G bore needle under the following parameters; .
Scaffold Preparation
10mm discs of scaffold were cut from the dry fibre sheet. The scaffolds were soaked in 70% isopropyl alcohol for 10 minutes, rinsed three times in phosphate buffered saline for 15 A c c e p t e d M a n u s c r i p t minutes each and allowed to dry completely at room temperature. Scaffolds were placed into an antibiotic/antimycotic treatment solution of Dulbeccos Minimal Essential Media supplemented with 100U/ml penicillin, 100µg/ml streptomycin, 0.25µg/ml Fungizone ® (amphotericin B) Anti-Anti solution (Gibco) for 1 hour.
Initial Layer Cell Seeding and Culture
Scaffolds were removed from the antibiotic/antimycotic treatment solution and rinsed three times for 15 minutes each in complete media; Dulbeccos Minimal Essential Media supplemented with 10% foetal bovine serum, 2mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin (Gibco). They were then placed into a fresh 48 well tissue culture plate. 5637 human urinary bladder epithelials (ATCC) were cultured and expanded as per supplier recommendations, using the media described above. Cells for scaffold seeding were trypsinized using 0.25% Trypsin-EDTA (Gibco) from tissue culture flasks and counted using the trypan blue exclusion method. 1 x 10 5 cells at passage 23 were suspended in 100µl of complete media and seeded directly on to the scaffolds. The cells were allowed to incubate in this small volume on the scaffolds for 2 hours, before an additional 400µl of complete media was added.
Media was changed after 24 hours using standard methods and subsequently changed every 48 hours. Controls were scaffold only, i.e. not seeded with an initial cell layer and a 'normal' initial layer i.e. untransfected cells. Initial layers of cells were cultured for 7 days at 37ºC and 5% CO2 in a humidified incubator.
Fibronectin Vector
Vectors were obtained from the DNASU plasmid repository. In brief, the human fibronectin gene (FN1) was placed into a retroviral expression vector, PJ1520. The insert sequence was verified by sequence analysis and restriction enzyme digest by DNASU. The vector was obtained in DH5-alpha T1 phage resistance Escheria coli glycerol stock. We cultured the E.
coli under selective conditions; 100µg/ml ampicillin, 34µg/ml chloramphenicol and 7%wt/vol A c c e p t e d M a n u s c r i p t sucrose in LB media. Plasmid extractions were performed using Cambridge Bioscience's Zyppy™ plasmid extraction kit following manufacturer's methods.
Transfections
Transfections were performed using Invitrogen Lipofectamine 3000 ® . Following titration experiments, a concentration of 1µg plasmid DNA and 0.75µL lipofectamine reagent per scaffold was chosen. The initial layer of 5637 epithelials was cultured on the scaffolds under standard conditions for 7 days. Transfection was performed on the 7 th day. Scaffold-cell constructs were then placed into selective media containing 150µg/ml puromycin. The cellscaffold constructs were cultured under selection for a further 7 days to allow production of the vector derived fibronectin before being decellularized.
Decellularization
Decellularization was performed under sterile conditions at room temperature (19 -22ºC) and with agitation. Scaffolds were placed into 50ml falcon tubes and placed on a rotator at 20RPM.
Scaffolds were washed with phosphate buffered saline (PBS) for 15 minutes and then rinsed in 10mM tris buffered saline (TBS) for 15 minutes.
The scaffolds were submerged in a 0.1% vol/vol Triton X-100 (Sigma-Aldrich) 1.5M potassium chloride (Acros Organics) 50mM TBS for 4 hours. They were rinsed for 15 minutes in 10mM
TBS before being submerged in fresh 10mM TBS overnight.
Scaffolds were given a final rinse in 10mM TBS for 15 minutes before being incubated in complete media for 15 minutes and then transferred to new 48 well plates for seeding.
Functional layer Cell Seeding and Culture
HepG2 cells were trypsinized using standard methods from tissue culture flasks and counted using the trypan blue exclusion method. 1 x 10 5 cells at passage 17 were suspended in 100µl
of complete media and seeded directly on to the scaffolds. The cells were allowed to incubate A c c e p t e d M a n u s c r i p t in this small volume on the scaffolds for 2 hours, before an additional 400µl of complete media was added.
Media was changed after 24 hours and changed every 48 hours after the initial 24 hour adherence and recovery period. This functional layer (FL) of cells was cultured using standard methods for either 3 or 5 days at 37ºC and 5% CO2 in a humidified incubator.
Live/Dead ® Viability/Cytotoxicity assay
To determine cellular viability, cell/scaffold constructs were incubated with 10µm calcein and 2µm ethidium ho-modimer-1 (Ethd-1) for 30 minutes as part of the two colour live/dead assay (Molecular Probes). Calcein is actively converted to calcein-AM in living cells, which then appear green when excited during fluorescence microscopy. Ethd-1 only accumulates in dead cells, which subsequently appear red. The method allows differentiation between dead and viable cells. The scaffolds were rinsed three times in CaCl2/MgCl2 free PBS to remove excess dye and placed onto a standard microscope slide with a 25mm glass coverslip (VWR). All images were captured using a Zeiss Axio Imager fluorescent microscope (COIL, University of Edinburgh) at 40x magnification and post processed using ImageJ.
CellTiter-Blue ® Cell viability assay
The assay was performed according to manufacturer's instruction (Promega). For each condition group, n = 5. Importantly, cell/scaffolds constructs were moved into fresh 48 well plates to prevent reading activity from tissue culture plastic bound cells. Measurements were read in a Modulus™ II microplate reader at an excitation wavelength of 525 nm and emission wavelength of 580-640 nm and reported as fluorescence.
Albumin quantification
A bromocresol green (BCG) albumin assay (Sigma) was used to quantify serum albumin produced by the HepG2 functional cell layer over 24 hours at 3 and 5 day timepoints. The A c c e p t e d M a n u s c r i p t assay was performed according to manufacturer's instructions and results read at an absorbance of 620 nm in a Modulus™ II microplate reader.
The Quant-IT™ Picogreen ® dsDNA assay kit (Life Technologies™) was employed to establish the efficiency of the decellularization method in removing cellular material and to estimate cell number on the cell/scaffold constructs. The assay was performed according to manufacturer instructions. In brief, constructs (n = 5) were digested in a solution of CaCl2 and MgCl2 free PBS (Sigma), containing 2.5 U/ml papain extract (Sigma) 5 mM cysteine-HCl (Sigma) and 5 mM EDTA (Sigma) and incubated for 48 hours at 60°C. Picogreen solution was added to the digests and fluorescent intensity measurements read in a Modulus™ II microplate reader at an excitation wavelength of 480 nm and emission wavelength of 510-570 nm. A standard λ dsDNA curve of graded known concentrations was used to calibrate fluorescence intensity vs dsDNA concentration.
Sectioning and staining
The samples were rinsed three times in PBS (Gibco) for 15 minutes each, then fixed in 4% v/v formalin buffered in saline for 15 minutes at room temperature. After rinsing with fresh PBS, constructs were embedded in low melting temperature polyester wax (Electron Microscopy Supplies) using methods adapted from Steele et al. (2014) . In brief, samples are dehydrated through 70-100% ethanol, then incubated in 50:50 ethanol:wax overnight at 45ºC overnight with agitation. The samples were moved into 100% wax for 3 hours at 45ºC and then fresh 100% wax for 1 hour at 45ºC. Samples were embedded and allowed 72 hours to fully cure before sectioning. Immunohistochemical staining was undertaken using antibodies for Collagen I (Stratech), Laminin (Stratech) and Fibronectin (Sigma). All images were captured using a Zeiss Axio Imager system (Centre Optical Instrumentation Laboratory, University of Edinburgh) at 40x magnification and post processed using ImageJ. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t
Scanning Electron Microscopy
SEM was used to characterise the scaffold architecture. Samples were rinsed three times in PBS for 15 minutes each, then fixed in 2.5% v/v glutaraldehyde (Fisher Scientific) in 0.1M phosphate buffer (PB) (pH 7.4) at 4ºC overnight. They were then rinsed three times in 0.1M PB before being post-fixed in 1% v/v osmium tetroxide (Electron Microscopy Supplies) buffered with 0.1M PB. Samples were again rinsed three times in 0.1M PB and dehydrated through an ethanol gradient (30-100%). They were dried by placing them in hexamethyldisilazane (HDMS, Sigma) which was allowed to evaporate off at room temperature overnight. We mounted the samples onto SEM chucks using double sided carbon tape and coated them with a thin layer of gold and palladium alloy (Polaron Sputtercoater).
All images were captured at 5 kV using a Hitach S-4700 SEM (BioSEM, University of Edinburgh).
Mechanical Testing
Nanoindentation experiments were undertaken to establish the dynamic properties of scaffolds and decellularized ECM/scaffold constructs using the Keysight/Agilent 5200 nano indenter testing system. Scaffolds and constructs were subject to indentation by a DCM II actuator flat-ended cylindrical punch (D = 100µm) using a max load of 1g-f. All nanoindentation experiments were carried out on fresh, hydrated (suspended in PBS), unfixed samples in a stainless steel well chuck. A total of 36 indentations were carried out on each sample, 50nm apart. Indent sites were selected using the high precision X-Y stage within the testing system (Agilent). Poissons ratio was assumed to be 0.5 for each sample 42, 43 . Allowable drift rate was 0.1nm/s. A NanoSuite (Keysight Technologies) test method "G-Series DCM CSM Flat Punch Complex Modulus" was used for all testing 44, 45 . A c c e p t e d M a n u s c r i p t
Gene Expression analysis
RNA was extracted from constructs using standard Trizol (Fisher Scientific) methods and purified using Qiagen's RNeasy spin column system. cDNA was synthesised using the Promega's ImProm-II™ Reverse Transcription System.
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the 
Statistical Analysis
One-way ANOVAs with Fishers, Games-Howell and Tukey 48-50 post-hoc testing were performed using Minitab 17 Statistical Software and graphs generated using Origin software (OriginLab, Northampton, MA). Error bars indicate standard deviation. A minimum of n = 3
and max of n = 6 was used for all analysis.
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Results
Cell attachment and survival on scaffolds
When compared to normal ECM derived from untransfected cells (N-ECM) and the scaffold alone (SO), a lower number of HepG2s adhered to the synthetically derived vector driven (SD-ECM) scaffold-ECM constructs (Fig. 1) . According to the CellTiter-Blue ® results (Fig. 1A) , the SD ECM layer maintained the growth of the HepG2s between days 3 and 5. However, this result is not concurrent with the Picogreen ® DNA quantitation (Fig. 1B) . A c c e p t e d M a n u s c r i p t
Mechanical characterisation of scaffolds
Reassuringly, both storage (G') and loss (G") modulus demonstrate significant differences between the three conditions (Fig. 3) . Fibronectin is known to influence both the mechanical profile of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t
Biochemical characterisation of the hybrid polymer-ECM scaffolds
Differences in the biochemical profile of the different ECMs were demonstrated by immunohistochemistry performed on decellularized hybrid scaffold sections (Fig. 4) . Hepatic cells are very responsive to extracellular matrix proteins; particularly Collagen I, Laminin and Fibronectin [56] [57] [58] .
Fibronectin is ubiquitous in healthy liver 59, 60 , and antibody staining reveals altered levels of fibronectin in the synthetically derived ECM, as expected due to the introduction of the fibronectin vector (Fig.   4H ).
ECM proteins do not exist in isolation, and fibronectin is known to influence the generation and laydown of other ECM proteins including collagen I and laminin 53, 61 , as evidenced in Fig. 4G and 4I when compared to N-ECM. The N-ECM is collagen I rich ( Fig. 4D ) with some fibronectin and laminin also present ( Fig. 4E & 4F) . Of note is that the SD-ECM appears to be concentrated on the outer layers of the electrospun scaffold. This could be due to the transfected cells being in fewer number than those which were not transfected (N-ECM), so they did not penetrate the scaffold to the same extent.
Gene expression of HepG2s in response to hybrid polymer-ECM scaffolds
Genes associated with both liver function and ECM production were assayed for gene expression ( A c c e p t e d M a n u s c r i p t the highest levels of expression observed in SO and SD-ECM conditions. Additionally, albumin mRNA expression is downregulated in comparison to TCP at day 3 in all conditions (Fig. 5A ).
Cytochrome P450s (Cyp) are a family of enzymes involved in metabolism of xenobiotics and toxic compounds in the liver [62] [63] [64] . Cyp1A1 mRNA expression is significantly altered in comparison to TCP (Fig. 5B) ; upregulated at day 3 and downregulated at day 5. Cyp1A2 mRNA expression is consistently significantly downregulated in all but one condition; day 3 N-ECM (Fig. 5C ). Cyp3A4 mRNA expression is upregulated in every condition, with a significant upregulation observed in response to SD-ECM (Fig. 5D ).
In addition, we assayed for three ECM genes important for normal liver composition 59, 65 ; Fibronectin (Fig. 5E ), Collagen I ( Fig. 5F ) and Collagen IV ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t alterations in gene expression are promising, we refrain from further assumption regarding cell response without further proteomic and functional analyses.
Albumin production
Albumin levels are indicative of hepatocyte health and response to the microenvironment 57 . Each condition results in differing levels of albumin production, with significant differences in protein levels observed between SO and SD-ECM at both 3 days and 5 days (Fig.   6 ), indicating that the N-ECM encouraged albumin production more than SD-ECM.
Confirmation of decellularization
Decellularization was confirmed using Picogreen® DNA quantitation (Fig. 7G) and histological staining (Fig. 7A-F) . A tenfold reduction in DNA combined with visual confirmation of an absence of DAPI nuclear staining and Phalloidin-514 actin staining on 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t decellularized constructs, plus the presence of fibronectin antibody staining on both the N-ECM and SD-ECM decellularized constructs (Fig. 7E&F) provides evidence of efficient decellularization methods, and that synthetically derived fibronectin is present on the hybrid scaffolds.
Discussion
The extracellular matrix provides a microenvironment for cells which is not yet fully understood, nor replicable by existing manufacturing methods 16, [67] [68] [69] . By manipulating human cells to produce a customizable blend of ECM components, and combining this with replicable electrospun scaffolds and decellularization methods we overcome the shortage of donor derived ECM bioscaffolds and the issues regarding animal-sourced biomaterials 16, 70 .
Additionally, this platform has the potential to be used to model not only 'healthy' ECM microenvironments, but also those of disease and developing states.
By using fibrous electrospun scaffolds we mimic the morphology of healthy fibrillary collagen 10, 11, 71, 72 . PLA was used to fabricate the scaffolds, chosen for its compatibility with hepatocytes 56 and its use in multiple types of medical device due to its predictable biodegradation rate and mechanical properties 73, 74 .
Fibronectin was chosen as our protein to synthetically overexpress due to its vital role in the liver 51, 75 and its interaction with other ECM components such as collagen and laminin 52, 53 .
Fibronectin is a large dimeric adhesive glycoprotein which exists in both cellular and plasma forms, with roles in regenerating tissues, embryonic development and regulation of cell behaviours such as adhesion and migration 76 . The role of fibronectin in the liver is still unclear, with inhibition of fibronectin production or deposition improving fibrosis outcomes 77, 78 .
However its vital role in the hepatic ECM is demonstrated by mutant mice who were specifically null in only the liver for both plasma and cellular fibronectin. The fibronectin-null livers not only develop highly disorganized/diffuse collagenous ECM networks, but when fibrogenesis was induced the null livers experienced more extensive fibrosis; thought to be 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t due to fibronectins role in regulating TGF-β1 bioavailability 75 . Additionally, homozygous fibronectin null mutants display early embryonic lethality, while heterozygotes (with 50% of the normal plasma fibronectin levels) appear normal; suggesting a dose dependent role for fibronectin in development 79 .
As an initial assessment of these novel hybrid scaffolds we investigated the attachment and function of a commonly used liver cell line, HepG2s, when cultured on the synthetically derived hybrid scaffolds versus a wild type 'normal' hybrid scaffold and the scaffold alone. The HepG2 cell line was derived from the hepatocarcinoma of a 15 year old Caucasian male. They are often used because they are virus free, possess liver specific functions such as ammonia metabolism and albumin synthesis and secrete some growth factors 80 . We analysed cell attachment and viability, albumin production and gene expression of both liver function genes and ECM genes at 3 and 5 day time points. Additionally, we validated our decellularization method and performed both immunohistochemical and raman spectrum analyses (data not shown) of the hybrid scaffold-ECM constructs upon which the HepG2s were seeded.
Our results indicate not only that synthetically derived ECMs provide a viable method of biofunctionalising electrospun polymer scaffolds, but that the composition of the synthetically derived ECM-polymer hybrid scaffolds influences liver cells. That albumin production is significantly altered between SO and SD-ECM conditions, but not N-ECM conditions supports this assertion. Gene expression of key hepatic genes was altered on day 5 of SD-ECM conditions in every gene tested, whereas SO and N-ECM conditions only influence CYP1A2 and COL4A1 expression; demonstrating that the composition of the ECM is highly influential in tissue engineering. This in turn leads to questions regarding donor-donor variability of current decellularization work and its influence upon hepatic behaviour and a need for more reproducible hepatic microenvironments that this platform provides.
The researchers responsible recognise that, while this study forms a robust initial proof of principle regarding the exploitation of synthetic biology for scaffold manufacture, and has produced a novel hybrid synthetically derived ECM-polymer scaffold with great potential for 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t liver tissue engineering, further work is required to analyse results and increase translatability.
Vector technologies and synthetic biology present obvious concerns with regards to patient safety 30, 81 , and care should be taken to ensure all bacterial/ viral constructs are removed from the ECM layer. Detergent based methods used to strip the ECM of cells can be detrimental to the bioscaffold 70, 82 , disrupting native tissue ultrastructure, decreasing glycosaminoglycan (GAG) content and reducing collagen integrity 83, 84 as well as disrupting lipid-lipid, lipid-protein and protein-protein interactions 85 . Care should be taken to optimise this procedure in the future. HepG2s provide a convenient method of initial viability testing of the scaffolds, but they are derived from a carcinoma and as such criticism of their clinical relevance is well placed.
Further studies will utilise primary or stem cell derived hepatocytes to combat such criticism.
Additionally, recognition of the value of further proteomic and functional assays (such as ELISAs and Alkaline Phosphatase quantitation) in analysing the function of hepatocytes will be vital for expanding this work, however at this time these were deemed unnecessary considering the obvious critiques of the use of the HepG2 cell line. Further, the importance of ensuring decellularization agents are removed from the constructs should not be underestimated, due to their influence upon cells and ECM 21, 70 . While such criticisms are important to consider, this work clearly demonstrates the potential of synthetic biology for the design of bespoke ECMs and provides a robust initial platform upon which further, improved studies can be built.
Conclusion
This study demonstrates a novel method of creating a biologically bespoke hybrid ECMpolymer scaffold; utilising clinically translatable electrospun scaffold technologies and synthetic biology methods both easily modified to fulfil Good Manufacturing Practice (GMP)
guidelines. In order to achieve this, a sacrificial ECM-producing cell layer was transfected using a protein producing fibronectin vector on an electrospun scaffold, biofuctionalizing the scaffold with a biologically bespoke ECM. Scaffolds with wild type untransfected cells and no initial cell layer at all were used as controls. This sacrificial cell layer was successfully removed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 These novel scaffolds exhibit great promise both as an implantable patient treatment for liver tissue engineering, for adaptation to other tissues and as a useful tool for development of 3D
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